Clinical Study

The Factors Which is Predict the Response to Neoadjuvant Chemotherapy in Stage IB2 Cervical Cancer

  • Nejat Özgül
  • Taner Turan
  • Iltaç Küçükelçi
  • Gökhan Tulunay
  • Nurettin Boran
  • Süha Özer
  • Iskender Kög
  • Mehmet Faruk Köse

Received Date: 15.12.2007 Accepted Date: 10.05.2008 J Turk Ger Gynecol Assoc 2008;9(3):152-157


The aim of the study was to determine the outcomes of neoadjuvant chemotherapy and its predicting factors in patients with stage IB2 cervical cancer.


The data of 36 patients with stage IB2 cervix carcinoma who received neoadjuvant chemotherapy are retrospectively reviewed. Chemotherapy protocols were cisplatin/5-fluorauracil, cisplatin/UFT and carboplatin/paclitaxel. After NACT, the patients were re-examined and the patients who had a tumor size less than 40mm were operated (type III radical hysterectomy) and radiotherapy was given to the others.


The mean age of patients was 46.3 years and the mean follow up was 46.5 months. The mean tumor size was 51.4mm before NACT and 32.7mm after NACT. While 12 patients (33.3%) had overall clinical response, complete clinical response was in four (11.1%), stabile disease was in 22 (61.1%) and progression was seen in two (5.6%). Clinical response was affected by age (≤45 vs >45). Tumor size before treatment, histopathology, chemotherapy protocol and the number of chemotherapy course hadn’t an effect on response.


In this study, the success of NACT was affected by age. The identifying of factors which is determines to outcome of this treatment modality improves the effectiveness of NACT.

Keywords: Stage IB2 cervical cancer, Neoadjuvant chemotherapy